| Ident. | Authors (with country if any) | Title |
|---|
| 000182 (2011) |
Natalie R. S. Goldberg [États-Unis] ; Tom Hampton [États-Unis] ; Scott Mccue [États-Unis] ; Ajit Kale [États-Unis] ; Charles K. Meshul [États-Unis] | Profiling changes in gait dynamics resulting from progressive 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced nigrostriatal lesioning |
| 000265 (2011) |
James A. Miller [États-Unis] ; Briana R. Trout [États-Unis] ; Kelly A. Sullivan [États-Unis] ; Russell A. Bialecki [États-Unis] ; Ruth A. Roberts [Royaume-Uni] ; Ronald B. Tjalkens [États-Unis] | Low‐dose 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor‐κB reporter mice prior to loss of dopaminergic neurons |
| 000630 (2010) |
Xiao-Qing Tang [République populaire de Chine] ; Yu-Juan Li ; Jing Zhao ; Xing-Tian Shen ; Chun-Tao Yang ; Li-Li Fan ; Bi Hu ; Yuan-Jian Li ; Duan-Fan Liao [République populaire de Chine] | Neuroprotective effect of asymmetric dimethylarginine against 1‐methyl‐4‐phenylpyridinium ion‐induced damage in PC12 cells |
| 000912 (2009) |
David A. Price [États-Unis] ; Alex A. Martinez [États-Unis] ; Alexandre Seillier [États-Unis] ; Wouter Koek [États-Unis] ; Yolanda Acosta [États-Unis] ; Elizabeth Fernandez [États-Unis] ; Randy Strong [États-Unis] ; Beat Lutz [Allemagne] ; Giovanni Marsicano [France] ; James L. Roberts [États-Unis] ; Andrea Giuffrida [États-Unis] | WIN55,212‐2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mouse model of Parkinson’s disease |
| 000A73 (2009) |
Na K. Kim [Corée du Sud] ; Byung H. Choi [Corée du Sud] ; Xian Huang [Corée du Sud] ; Brian J. Snyder [Canada] ; Shefqat Bukhari [Canada] ; Tae-Ho Kong [Corée du Sud] ; Hyeonseon Park [Corée du Sud] ; Hyung C. Park [Corée du Sud] ; So R. Park [Corée du Sud] ; Yoon Ha [Corée du Sud] | Granulocyte–macrophage colony‐stimulating factor promotes survival of dopaminergic neurons in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced murine Parkinson’s disease model |
| 000B82 (2009) |
Pablo Garrido-Gil [Espagne] ; Silvia Belzunegui [Espagne] ; Waldy San Sebastián [Espagne] ; Amaya Izal-Azcárate [Espagne] ; Berta L Pez [Espagne] ; Irene Marcilla [Espagne] ; Maria Rosario Luquin [Espagne] | 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure fails to produce delayed degeneration of substantia nigra neurons in monkeys |
| 000F50 (2007) |
M. J. Hurley [Royaume-Uni] ; P. H. Patel [Royaume-Uni] ; M. J. Jackson [Royaume-Uni] ; L. A. Smith [Royaume-Uni] ; S. Rose [Royaume-Uni] ; P. Jenner [Royaume-Uni] | Striatal leucine‐rich repeat kinase 2 mRNA is increased in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned common marmosets (Callithrix jacchus) with l‐3, 4‐dihydroxyphenylalanine methyl ester‐induced dyskinesia |
| 001223 (2006) |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa‐induced dyskinesias by a selective NR1A/2B N‐methyl‐D‐aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin |
| 001392 (2005) |
Mahmoud M. Iravani [Royaume-Uni] ; Sergio Costa [Royaume-Uni] ; Ghassan Al-Bargouthy [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Bai-Yun Zeng [Royaume-Uni] ; Mikko Kuoppam Ki [Royaume-Uni] ; Jose A. Obeso [Espagne] ; Peter Jenner [Royaume-Uni] | Unilateral pallidotomy in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmosets exhibiting levodopa‐induced dyskinesia |
| 001484 (2005) |
Guo-Hua Fan [République populaire de Chine] ; Chen Qi [République populaire de Chine] ; Sheng-Di Chen [République populaire de Chine] | Heat shock proteins reduce toxicity of 1‐methyl‐4‐phenylpyridinium ion in SK‐N‐SH cells |
| 001B94 (2000) |
E. Kwan [Canada] ; G. B. Baker [Canada] ; A. Shuaib [Canada] ; L. Ling [Canada] ; K. G. Todd [Canada] | N‐methyl,N‐propargyl‐2‐phenylethylamine (MPPE), an analog of deprenyl, increases neuronal cell survival in thiamin deficiency encephalopathy |
| 001D90 (1999) |
J. W. Langston [États-Unis] ; L. S. Forno [États-Unis] ; J. Tetrud [États-Unis] ; A. G. Reeves [États-Unis] ; J. A. Kaplan [États-Unis] ; D. Karluk [États-Unis] | Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure |
| 001E86 (1998) |
Ajay Madan [États-Unis] ; Andrew Parkinson [États-Unis] ; Morris D. Faiman [États-Unis] | Identification of the Human P‐450 Enzymes Responsible for the Sulfoxidation and Thiono‐Oxidation of Diethyldithiocarbamate Methyl Ester: Role of P‐450 Enzymes in Disulfiram Bioactivation |
| 002346 (1995) |
A. Espino [Espagne] ; J. Llorens [Espagne] ; M. Calopa [Espagne] ; R. Bartrons [Espagne] ; E. Rodriguez-Farre [Espagne] ; S. Ambrosio [Espagne] | Cerebrospinal dopamine metabolites in rats after intrastriatal administration of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium ion |
| 002415 (1994) |
F. Villa [Italie] ; R. Arnaboldi [Italie] ; B. Ghigini [Italie] ; A. Gorini [Italie] | Parkinson-like disease by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity in Macaca Fascicularis : Synaptosomal metabolism and action of dihydroergocriptine |
| 002506 (1993) |
T. Klockgether [Allemagne] ; P. Jacobsen [Danemark] ; -A. Löschmann [Allemagne] ; L. Turski [Allemagne] | The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist |
| 002514 (1993) |
Ajay Madan [États-Unis] ; Andrew Parkinson [États-Unis] ; Morris D. Faiman [États-Unis] | Role of flavin-dependent monooxygenases and cytochrome P450 enzymes in the sulfoxidation of S -methyl N , N -diethylthiolcarbamate |
| 002529 (1993) |
G. Bernocchi [Italie] ; G. Gerzeli [Italie] ; E. Scherini [Italie] ; C. Vignola [Italie] | Neuroprotective effects of α-dihydroergocryptine against damages in the substantia nigra caused by severe treatment with 1-methyl-4-phenyl-1,3,3,6-tetrahydropyridine |
| 002815 (1989) |
F. Boomsma [Pays-Bas] ; D. Meerwaldt [Pays-Bas] ; J. Man In'T Veld [Pays-Bas] ; A. Hovestadt [Pays-Bas] ; H. Schalekamp [Pays-Bas] | Treatment of idiopathic parkinsonism with l -dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of l -dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa |
